首页> 美国卫生研究院文献>Schizophrenia Bulletin >F225. LEVODOPA AUGMENTATION OF ANTIPSYCHOTICS FOR THE TREATMENT OF NEGATIVE SYMPTOMS IN SCHIZOPHRENIA
【2h】

F225. LEVODOPA AUGMENTATION OF ANTIPSYCHOTICS FOR THE TREATMENT OF NEGATIVE SYMPTOMS IN SCHIZOPHRENIA

机译:F225。左旋多巴加强抗精神病药治疗精神分裂症的症状。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

BackgroundNegative symptoms (i.e., motivation deficits and diminished emotional expression) are prevalent in schizophrenia and consistently linked with functional impairment for affected individuals. Despite advances in psychopharmacology for schizophrenia, there remain no effective treatments for these negative symptoms. Older literature, however, suggests that levodopa in conjunction with antipsychotic treatment can have beneficial effects for patients with schizophrenia. While supporting the safety and potential efficacy of dopamine augmentation, these studies did not evaluate effects within specific symptom domains, particularly negative symptoms. This open-label pilot study was conducted to evaluate the preliminary efficacy and safety of levodopa augmentation of antipsychotics for the treatment of negative symptoms.
机译:背景精神分裂症中普遍存在负性症状(即动机不足和情绪表达减弱),并且与受影响个体的功能障碍密切相关。尽管精神分裂症的心理药理学有所进步,但仍没有有效的方法治疗这些阴性症状。但是,较早的文献表明,左旋多巴与抗精神病药物联合治疗可对精神分裂症患者产生有益的作用。尽管支持多巴胺增强的安全性和潜在疗效,但这些研究并未评估特定症状域内的影响,尤其是阴性症状。这项开放标签的初步研究旨在评估左旋多巴抗精神病药增强剂治疗阴性症状的初步疗效和安全性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号